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Mechanisms affecting the development of renal cystic disease induced
by diphenylthiazole. To provide information on the possible influence
that hypertension or its treatment might have on the development of
cysts in autosomal dominant polycystic kidney disease, we studied the
effects of the sodium content of the diet, DOCA-salt hypertension,
renovascular hypertension, and the administration of enalapril or furo-
semide on the development of 2-amino-4-5-diphenylthiazole (DPT)-
induced renal cystic disease. DOCA-salt hypertension cailsed vascular
and glomerular lesions and proteinuria, but it did not enhance the
development of cysts. Cystogenesis was enhanced in experimental
conditions where the renin-angiotensin system is known to be activat-
ed. On the other hand, interventions known to suppress the renin-
angiotensin system lessened the development of cysts. We hypothesize
that this effect might be mediated by intrarenal angiotensin II and its
capacity to promote cell growth and to control the postglomerular
vascular resistances and the compliance of the renal interstitium.
Autosomal dominant polycystic kidney disease (ADPKD) is
characterized by progressive cystic transformation and enlarge-
ment of the kidneys. It has a variable clinical expression that
ranges from asymptomatic forms compatible with normal life
expectancy to end-stage renal failure during the adult life [1—61.
The mechanisms responsible for the formation of the cysts are
not clearly understood. Hypotheses currently entertained are:
(I) abnormal proliferative potential of the tubular epithelium
[7]; (2) partial tubular obstruction by polypoid epithelial hyper-
plasia [8—101; (3) increased tubular wall compliance [111; (4)
active transport and intraluminal accumulation of impermeant
organic anions [12—161. How additional pathophysiological
mechanisms can affect cystogenesis and alter the expression of
this disease is uncertain. To provide information on this unex-
plored aspect of the pathogenesis of ADPKD, we used a
chemical model induced by 2-amino-4-5-diphenylthiazole (DPT)
[10, 111. We studied the development of DPI-induced renal
cystic disease (DPT-RCD) under a variety of conditions includ-
ing high and low sodium diets, DOCA-salt hypertension, reno-
vascular hypertension, and administration of enalapril or furo-
semide. The experiments reported here suggest that maneuvers
that activate the renin-angiotensin system enhance while inter-
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ventions that inhibit the renin-angiotensin system lessen the
development of cysts.
Methods
Experimental protocols
Effect of DOCA-salt hypertension on the development of
DPT-RCD, Fourteen male Sprague-Dawley rats weighing 125 to
150 grams underwent a right nephrectomy. One week later they
were placed in metabolic cages and divided into two groups.
The rats in the first group (DOCA-HS) were fed an ICN
research diet (#902903) supplemented with 0.8% sodium chlo-
ride, were given 1% saline for drinking, and received weekly
subcutaneous injections of 10 mg of desoxycorticosterone
pivalate (Percorten, CIBA). The rats in the second group
(DOCA-LS) were fed a sodium deficient diet (ICN #902903),
were given water for drinking, and received weekly subcutane-
ous injections of 10 mg of desoxycorticosterone pivalate.
DOCA-HS and DOCA-LS rats were pair fed. Two weeks after
the right nephrectomy, 1% DPT (Travenol Laboratories, Inc.,
Deerfield, Illinois, USA) was added to the diets of both groups
of animals. Two DOCA-HS rats died in the course of the
experiment. During the last week of the experiments, the
concentration of NaCI in drinking water of DOCA-HS rats was
reduced to 0.5% because of the development of mortality in this
group, The food intake and urine output were measured daily.
Body weight and systolic blood pressures by the tail cuff
method were measured weekly in conscious animals, After six
weeks of exposure to DPT and after overnight deprivation of
food, the rats were anesthetized with mactin (Promonta, Ham-
burg, GDR), 100 mg/kg/body weight intraperitoneally. Three
rats from each group were placed on a heated table to maintain
the body temperature of 36 to 39°C. After tracheostomy,
catheters were inserted in both jugular veins for infusions, in a
carotid artery for withdrawal of blood and for pressure moni-
toring, and the dome of the bladder for urine collection. They
were primed with 0.5 ml of 2.5% inulin/2.5% PAH in 0.9%
saline solution, and the rate of the inulin/PAH infusion was kept
at 1.2 mI/hour throughout the course of the experiment. An
iso-oncotic solution was infused at the rate to equal 1% body
weight for one hour to replace surgical loss. Following this
recovery period, the left kidney was exposed through a small
left subcostal incision and placed in a lucite holder for micro-
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puncture studies. Five measurements of proximal tubular pres-
sure using micropipettes sharpened to I to 3 LMand a servo-
nulling device were obtained in each rat. A timed urine collec-
tion was obtained for clearance studies. In all the rats, the aorta
was then catheterized below the renal arteries and clamped
above the renal arteries, and the renal vein was sectioned to
allow perfusion fixation of the left kidney with Trump's solu-
tion. Then, the left kidney was removed, weighed, and proc-
essed for light microscopy and immunohistochemical studies.
Effect of the sodium content of the diet and enalapril treat-
ment on the development of DPT-RCD. Twenty-four male
Sprague-Dawley rats weighing 125 to 150 grams were divided
into four groups and kept in metabolic cages. The low salt (LS)
group was fed a sodium-free diet (ICN #902903) and given
water for drinking. The high salt (HS) group was fed an ICN
research diet #902903 supplemented with 0.8% sodium chloride
and given 1% saline for drinking. The low salt enalapril (LSE)
group was fed a sodium-free diet and given water containing 50
mg/liter of enalapril for drinking, The high salt enalapril (HSE)
group was fed an ICN diet #902903 supplemented with 0.8%
sodium chloride and given 1% saline containing 25 mg/liter of
enalapril for drinking. One percent DPT was added to the diet of
all four groups. The food intake and urine volumes were
measured daily, the body weights weekly, and systolic blood
pressures by the tail cuff method every two weeks. After eight
weeks of exposure to DPT, the rats were anesthetized and
prepared for clearance, micropuncture, and histologic studies
as described above. In this protocol, micropuncture studies
were attempted in all the rats, and interstitial hydrostatic
pressures using a subcapsular micropipet technique were mea-
sured in addition to proximal tubular pressures. At the end of
the experiments, the arterial blood pressure response to the
intravenous administration of angiotensin I (100 ng) and of
angiotensin 11(20 ng) were measured to determine the degree of
converting enzyme inhibition achieved by the administration of
enalapril.
Effect of two kidney, one-clip Goldhlatt hypertension on the
development of DPT-RCD. Twenty male Sprague-Dawley rats
weighing 100 to 125 grams had a U-shaped silver clip with a
preset 0.25 mm opening placed around the left renal artery
under pentobarbital anesthesia (50 mg/kg intraperitoneally).
They were maintained in metabolic cages on a standard rat diet
and water ad libitum. One week later, 1% DPT was added to the
diet. Food intake and urine output were measured daily, body
weights were measured weekly, and tail systolic blood pres-
sures by the tail cuff method were determined every other
week. Three rats died during the course of the experiments.
After six weeks of exposure to DPT, the rats were anesthetized
and prepared for clearance and histologic studies as described
above. Two additional rats were excluded because their left
kidney was found to be infarcted. No micropuncture studies
were performed in this protocol.
Effect of furosemide administration on the development of
DPT-RCD. Twenty male Sprague-Dawley rats weighing 100 to
150 grams were kept in metabolic cages on a standard rat diet
and water ad libitum. Furosemide was added to the drinking
water often rats in the experimental group, while the remaining
ten animals were used as controls. The concentration of furo-
semide was 20 mg/liter during the first month and 5 mg/liter
during the second month. One percent DPT was added to the
diet of both groups three days after starting the administration
of furosemide. Food intake and urine outputs were measured
daily, body weights were measured weekly, and tail systolic
blood pressures by the tail cuff method were determined every
other week. One rat in the furosemide treated group died after
three weeks, and two additional rats in the same group were
excluded because of failure to thrive. After eight weeks of
exposure to DPT, the rats were anesthetized and prepared for
clearance studies as described above. At the end of the study,
the kidneys were removed, bivalved, weighed, and processed
for histology as indicated above, with the exception that perfu-
sion fixation was not used in this protocol.
Laboratorj methods
Determinations of serum creatinine [17], plasma sodium and
potassium, urine protein concentrations 18], and and
CPAH [19] were measured by the methods routinely used in our
laboratories.
Morphologic analysis
The severity of the cystic disease was evaluated in coronal
sections (4 m) of the kidneys stained with periodic acid-Schiff
(PAS). The cystic lesions were semiquantitatively graded using
established criteria as follows: 0 = absence of the lesion, 1 =
lesion represented in <10% of the tissue with minimal change:
2 = lesion represented in up to 50% of the tissue and with
moderate change; 3 = lesion represented in 50 to 90% of the
tissue and with moderate change; and 4 = lesion represented in
over 50% of the tissue with severe change [20, 21]. Renal renin
content was semiquantitatively assessed in deparaffinized tissue
sections stained by the indirect immunoperoxidase technique
with the use of rabbit anti-rat renin antibodies [22] and the
HistoGen peroxidase/anti-peroxidase (PAP) immunohistology
staining kit. The rabbit anti-rat antiserum was from Vanderbilt
School of Medicine, Nashville, Tennessee, USA. The number
of juxtaglomerular apparatus (JGA) and isolated arterioles
containing cells with renin immunoreactivity were counted and
factored by the total number of glomeruli examined (Fig. I).
The number of glomeruli examined per kidney was 242 41
(SD). All morphologic analyses were done blindly.
Statistical analysis
Comparisons between groups in protocols A, C, and D were
made using the t-test for unpaired observations. In protocol B,
a two-way analysis of variance was used to analyze the two-
factor design (salt intake and administration of enalapril) look-
ing for both the main effect of these factors and their interac-
tion. In addition to this two-way analysis of variance, individual
means were compared using the least significant difference test
[231. The t-test for paired observation was used to compare the
clipped and contralateral kidneys in protocol C.
Results
Effect of DOCA -salt hypertension on DPT-RCD
The changes in systolic blood pressure, body weight, and
urine outputs in the DOCA-HS and DOCA-LS groups are
illustrated in Figure 2. The systolic blood pressure and urine
output were significantly higher in the DOCA-HS group. Table
1 summarizes the renal functional and morphological parame-
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I 1132 Torres et al. Sodium, angiotensin and cyst formationTable 1. Effect of DOCA-salt hypertension on the development ofDPT-RCDDOCA-HSN5 DOCA-LSN7
Urine Na mEqiday 16.5 1.2 0.1 O.1
Serum creatinine mg/dl 0.7 0.1 0.9 O.l
C1,11 mI/mid' 0.6 0.1 0.6 0.2
CPAH ml/minb 2.0 0.2 2.1 0.8
Plasma Na 149 1 147 1
P1asmaK 2.8±0.1 3.7±0.1'
Proteinuria mg/dI 235 132 23 l4
Kidney/body weight x 100 1.4 0.2 1.3 0.1
Cyst pathology score 1.6 0.7 3.3 l.0'
Renin score 0.5 0.3 10.6 3.1
Mean SEM
a Different from DOCA-HS, P < 0.05
b Measurement in 3 animals in each group
histologic examination (Fig. 3). On the other hand, DOCA-LS
rats had more severe cystic disease and absence of glomerular
and vascular lesions. Tissue renin immunoreactivity was signif-
icantly higher in the DOCA-LS group. Proximal tubular pres-
sures, which were measured only in three DOCA-HS and three
DOCA-LS animals, were found to be significantly higher in the
DOCA-LS rats with more severe cystic disease, 24 I (sEM)
compared to 18 2 mm Hg in the DOCA-HS rats.
ters at the end of the experiment. No differences in serum
creatinine, renal clearances, and kidney weight corrected by
body weight were observed. Plasma potassium was significantly
lower in the DOCA-HS rats. These rats also had marked
proteinuria and severe vascular and glomerular lesions on
The effect of the sodium content of the diet and
administration of enalapril on the development of DPT-RCD
The changes in systolic blood pressure, body weight, and
urine outputs during the course of the experiments are illus-
trated in Figure 4. The urine outputs were significantly higher in
the high-salt groups as compared to the low-salt groups. Table
2 summarizes the renal functional and morphological parame-
ters at the end of the experiments. Using a two-way analysis of
variance, both the administration of salt (P = 0.038) and the
administration of enalapril (P = 0.059) had an independent
protective effect on the pathology score, but only the adminis-
tration of salt had an effect on the corrected kidney weights (P
= 0.032) and (P = 0.056). Representative examples of' the
cystic disease noted in these animals are shown in Figure 5.
Tissue renin immunoreactivity was significantly higher in LS
rats than in HS rats. At the end of the experiment, the relative
hypertensive response to the administration of angiotensin I as
compared to that of angiotensin II in the rats treated with
enalapril was 34.5% of that observed in the animals not receiv-
ing this drug. Hydrostatic pressures measured during the mi-
cropuncture studies are illustrated in Figure 6. Although prox-
imal tubular pressures and the gradient of pressure across the
tubular wall tended to be higher in LS rats, the differences did
not reach statistical significance.
Effect of two kidney, one-clip Goldblatt hypertension on the
development of DPT-RCD. Five of the 15 rats did not develop
hypertension, defined as a systolic tail blood pressure 150 mm
Hg or a mean arterial pressure 135 mm Hg. These five
normotensive rats were considered to be clip-controls without
stenosis (group clip-CN). The remaining 10 hypertensive ani-
mals formed the renal artery stenosis group (group RAS). No
significant differences in body weight or urine output were
Fig. 1. Sections of a kidney of a DPT-treated rat stained by the PAP
method with antibodies to renin. Renin positivity in the juxtaglomerular
cells of the afferent arteriole. Note dilated distal convoluted tubules.
250 - DPT
5-DE 100 -g 50 -
I I I I I I I
- 240
140 I I I I I I I I
150 -
Time, weeks
Fig. 2. Changes in systolic blood pressure, body weight, and urine
output in the DOCA-HS (—) and DOCA-LS () groups during
the course of the experiment.
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noted between these two groups (Fig. 7). Food intake was also
similar. Table 3 summarizes the renal functional and morpho-
logical parameters at the end of the experiment. The rats with
Effect of furosemide administration on the development of
DPT-RCD. The changes in systolic blood pressure, body
weight, and urine output during the course of the experiments
are illustrated in Figure 9. The urine output was significantly
higher in the furosemide treated group. Table 4 summarizes the
functional and morphological parameters at the end of the
experiment. The furosemide treated rats had more severe cystic
disease as reflected by the higher kidney weight and pathology
score and the lower renal clearances. Representative examples
of the cystic disease noted in these animals are shown in Figure
10. This group also had a significantly lower plasma potassium.
Discussion
ADPKD is a common inherited disease characterized by
progressive cystic transformation and enlargement of the kid-
neys. Morphological, biochemical, and functional studies of
human polycystic kidneys indicate that these cysts derive from
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Fig. 3. Coronal Section (A) and light photomicrograph (B) ofa DOCA-HS kidney illustrating severe vascular and glomerular lesions. Coronal
section (C) and light photomicrograph (D) ofa DOCA-LS kidney illustrating marked cystic tubular dilatation. PAS stain.
250 — DPT significant renal artery stenosis had more severe cystic disease
200 - as reflected by higher total kidney weights and more cysts in
150 -
___ ______ both kidneys. In addition, the cystic disease in the RAS animals
100 - was more severe in the left clipped kidney than in the contra-
50 - lateral kidney (cyst grade 2.6 0.3 versus 1.9 0.4, P 0.041).
0 I I I Representative examples of the cystic disease observed in these
250 -
—
animals are shown in Figure 8. Tissue renin immunoreactivity
——
was also significantly higher in the clipped kidney than in the
:::
I I
contralateral kidney (renin score 24.1 3.5 vs. 11.7 1.9, P =
75
50
25
0 1 2 3 4 5 6 7 8 9
Time, weeks
Fig. 4. Changes in systolic blood pressure, body weight, and urine
output in LS (—), HS (—), LSE (n), and HSE (
groups during the course of the experiment.
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Table 2. Effect of sodium content on the development of DPT-RCD
LS HS LSE
--______________________
HSEN=6 N—6 N=6 N=6
Urine Na 0.1 0.1 9.2 0.9° 0.1 0.1 10.3 0.60
C11, mi/mm 0.7 0.2 1.3 0.4 1.0 0.1 1.6 0.4°
CPAH mi/mm 3.0 0.6 4,9 1.1 5.4 0.6 6.6 1.8°
Plasma Na 151 1 152 1 150 1 152 I
Plasma K 3.3 0.2 3.1 0.2 3.4 0.3 3.4 0.3
Kidney/body weight x 100 2.2 0.2 1.8 0.1° 1.9 0.1 1.6 0.I'
Cyst pathology score 3.0 0.5 2.0 0.4° 2.1 0.4 1.4 0.2°
Renin score 17.9 2.1 5.1 1.8° — —
Mean SEM0 Different from LS, P < 0.05
C)I
E
E
C)I
E
E
lsvstoli[LL
0 1 2 3 4 5 6
Time, weeks
a relatively small number of focal dilatations of tubules, may or
may not remain connected to these structures, and retain some
of the functional characteristics of the tubular segments from
which they derive [24—341. The severity of the disease varies
markedly from patient to patient [1—61. While in some patients
the disease remains clinically silent, many develop hyperten-
Fig. 7. Changes in arterial blood pressure, body weight, and urine
output in RAS (_, L) and Clip-CN (—, 1) groups during the
course of the experiment.
sion or suffer deterioration of renal function, presumably due to
damage to the renal parenchyma by the expanding cysts.
Although different hypotheses have been proposed to explain
150
100
50
0
Fig. 6. Hydrostatic pressures measured during the micropuncture
studies in groups LS (), HS (E), LSE (LII), and HSE (). N = number
of animals studied. At least five tubular and two subcapsular pressures
were measured in each animal.
DPT MAP
(CO(DO COLOIfl LO.JLO C)L()
II II II It II II II II II II II II II II II
C) 180
160
140
120
a
C)
C)
200
50
25Fig. 5. Representative coronal sections illustrating the cystic disease
noted in LS (A), LSE (B), HS (C), and HSE (D) rats.
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Fig. 9. Changes in systolic blood pressure, body weight, and urine
output in the furosemide treated () and control (.—)groups
during the course of the experiment.
Table 4. The effect of furosemide administration on the development
of DPT-RCD
Furosemide
N=7
Control
N=lO
C101 mi/mm 0.7 0.la 1.2 0.2
CPAH mi/mm 2.5 0.3 3.8 0.3
Plasma Na mEqIL 149 1 146 2
Plasma K mEqIL 2.8 0.3a 3.6 0.2
Kidney/body weight x 100 1.5 0.Ia 11 0.1
Cyst pathology score 2.7 0.3a 1.7 0.2
Renin score 19 5 14 3
Mean SEM
a Different from control, P <0.05
Fig. 8. Representative coronal sections of clipped (left panel) and
contralateral (right panel) kidneys in Protocol C. (A, B and C) Group
RAS. (D) Group CLIP-CN.
the process of cyst formation [7—161, neither the primary cause
of the disease nor the factors that determine the variability of
expression are well understood. For example, ADPKD patients
who have hypertension at the time of their initial diagnosis are
more likely to progress to end-stage renal failure [2]. Whether
transmission of arterial hypertension to the kidney or its treat-
ment influences the development of cysts has not been studied.
To provide information in this area, we studied the effects of
high and low sodium diets, DOCA-salt hypertension, renovas-
cular hypertension, and the administration of enalapril or furo-
semide on the development of an experimental model of renal
cystic disease induced by DPT.
Whether chemically-induced renal cystic disease is a satis-
factory model for ADPKD is uncertain. This experimental
model and the human disease have in common, in addition to
the presence of enlarged and cystic kidneys, the development of
epithelial hyperplasia [10, 35—37], the predominant involvement
of the collecting ducts [10, 11, 37], and the loss of basement
membrane and interstitial sulfated proteoglycans [38]. The
cystic disease, however, develops more acutely and the tubular
dilatation is more diffuse in the chemical model than in
ADPKD. Therefore, although the observations made in this
model may be relevant to the pathogenesis of ADPKD, the
Table 3. The effect of two kidney, one-clip Goldblatt hypertension on
the development of DPT-RCD
- DPT
1
RAS
N=lO
CLIP-CN
N=5
mI/mm 1.5 0.4 1.7 0.1
CPA!.! mI/mm 5.5 1.0 7.3 0.9
Total kidney/body wt x 100 1.23 0.05k' 0.97 0.05
Rt. kidney/body wt x 100 0.73 0.06k' 0.49 0.02
Lt. kidney/body wt x 100 0.50 0.06 0.48 0.04
Pathology score rt. kidney 1.9 0.3 1.1 0.1
Pathology score lt. kidney 2.6 0.3a 1.2 0.2
Renin score rt. kidney 11.7 1.9 —
Renin score It. kidney 24.1 3.5 —
a) !DU
140
130
120>..(n1) 110
ci 100
90
Mean SEM
a Different from CLIP-CN, P < 0.05
I I I I I I
a)
.D .COa)
03
cE
0 1 2 3 4 5 6 7 8
Time, weeks
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Fig. 10. Representative coronal sections
illustrating the cystic disease noted in the
furosemide treated (A) and control rats (B).
conclusions cannot be directly extrapolated from this experi-
mental model to the human disease.
The results of our study indicate that DPT-RCD is enhanced
by sodium restriction, renovascular hypertension. and admin-
istration of furosemide. Common to all these experimental
conditions is the stimulation of the renin-angiotensin system.
Conversely, maneuvers that inhibit the renin-angiotensin sys-
tem, such as sodium loading, DOCA-salt hypertension, and
administration of enalapril, lesscned the development of cysts.
The mechanism responsible for the observed effects is uncer-
tain, and the interpretation of these observations can at present
be only speculative.
First, the possibility that these experimental maneuvers
might have altered the metabolism of DPT or the renal handling
of DPT or its metabolites should be considered. Following
administration, DPT is mostly concentrated and metabolized in
the liver. Neither DPT nor its metabolites are concentrated in
the medulla or papilla of the kidney as compared to the outer or
inner cortex [39]. It seems, therefore, unlikely that the in-
creased severity of the cystic disease in some of our experi-
mental groups could be explained by an increased corticomed-
ullary concentration gradient and accumulation of DPT or its
metabolites in the renal medulla. It is also unlikely that differ-
ences between the groups could be explained by differences in
urine flow, since furosemide treated animals had more severe
disease than their controls despite much higher urine outputs,
and there was no correlation between the severity of the cystic
change and the urine volumes in the groups of rats treated with
low or high sodium diet with or without enalapril.
Hypokalemia in rodents can cause hyperplasia of the collect-
ing tubule cells, obstruct the tubular lumen, and cause tubular
dilatation proximal to the hyperplasia [40]. Since DOCA-salt
and furosemide treated rats had lower plasma potassium levels,
hypokalemia might have contributed to the development of the
cystic disease in these two groups of animals. We have recently
described in patients with primary hyperaldosteronism and
severe hypokalemia the presence of medullary cysts that de-
crease in size or resolve following correction of the hypokale-
mia [41]. It seems unlikely, however, that hypokalemia played
a major role in the DOCA-salt treated rats. Despite the presence
of hypokalemia, the DOCA-salt treated animals had similar
kidney weights and less severe cystic disease than the DOCA-
treated salt restricted rats. Hypokalemia on the other hand may
have contributed to the increased severity of the renal cystic
disease in the furosemide treated rats. These animals had more
severe cystic disease than their controls despite the fact that
furosemide [42], as other loop diuretics [431, can at high
concentrations reduce the rate of growth of MDCK cysts in
hydrated collagen gel.
Increasing attention has been paid to angiotensin II as a
growth promoting factor. Angiotensin II stimulates phosphatid-
yl-inositol breakdown causing release of intracellular second
messengers and activation of enzymes that control cell growth
in a variety of cell types, including renal tubular cells [44—46].
Physiological concentrations of angiotensin II enhance prolifer-
ation of cultured vascular smooth muscle [47] and adrenocorti-
cal cells [481. Recently, physiological concentrations of angio-
tensin II have been found to enhance the sensitivity of renal
proximal tubular cells in culture to the mitogenie effect of
epidermal growth factor [49]. Thus, our observations in DPT-
induced renal cystic disease, which as many other renal cystic
diseases is characterized by the presence of a hyperplastic
response of the tubular epithelium, could be explained by the
growth promoting activity of angiotensin II. Measurements of
tissue renin immunoreactivity in our study support this possi-
bility. Nevertheless, neither tissue renin nor plasma renin
activity correlate well with tissue angiotensin II levels [50]. For
example, after three weeks of sodium loading plasma renin
activity and kidney renin concentration are suppressed, but
intrarenal angiotensin H is not [50]. This may explain the
w
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additional protective effect of enalapril when added to a high
salt diet in our study. In two kidney, one-clip Goldblatt hyper-
tension the concentration of intrarenal angiotensin II is in-
creased in the clipped kidney, but it is not suppressed in the
contralateral kidney compared to a control animal [501. This
and observations made by others that elevated circulating
angiotensin II levels in two kidney, one-clip Goldblatt hyper-
tensive rats exert substantial influence on the hemodynamic and
excretory function of the nonclipped kidneys [51—53] may
explain why contralateral kidneys in our study had less severe
cystic disease than clipped kidneys but were not protected
when compared to the clip-control kidneys.
The renin-angiotensin system might also influence the proc-
ess of cyst formation by controlling the mechanical pressures
acting on the tubular wall, that is, the hydrostatic tubular and
interstitial pressures and the interstitial gel tissue pressure.
There have been many studies of hydrostatic tubular and
interstitial pressures as they relate to sodium transport [54, 551.
For example, in DOCA-salt hypertension, preglomerular vas-
cular resistances are selectively increased [56] while the renin-
angiotensin system is suppressed and there is little change or a
reduction of postglomerular vascular resistances. As a result,
peritubular capillary and interstitial hydrostatic pressures are
elevated [57], while intratubular pressures remain unchanged
[56]. On the other hand, sodium depletion preferentially in-
creases postglomerular vascular resistance [58, 59] and results
in a reduction of the interstitial hydrostatic pressure. Under
these conditions, the pharmacologic blockade of the renin-an-
giotensin system, which has a selective effect on postglomerular
vascular resistances [60], causes a significant increase in hydro-
static peritubular capillary and interstitial pressure [61]. The
predictable effects of these experimental maneuvers on the
gradient of hydrostatic pressure across the tubular wall corre-
late well with the effects that these interventions had on the
development of DPT-RCD. Nevertheless, in our small number
of observations, made at single time points when severe cystic
disease had already developed, we could not demonstrate
significant reductions in hydrostatic interstitial pressure or
higher gradients of hydrostatic pressure across the tubular wall
in the rats with more severe cystic disease.
Finally, the renin angiotensin system might also have an
effect on cyst formation by altering interstitial gel tissue pres-
sure and the compliance of the interstitial gel. The interstitial
gel pressure is the pressure exerted by the interstitial gel, as
opposed to the interstitial hydrostatic pressure which is a
pressure of the freely mobile fluid in interstitial spaces [62, 63].
The interstitial gel holds water by osmotic forces [64—661. The
gel tension is determined by the return of fluid by osmotic
forces after the gel has been compressed and fluid expelled. It is
higher when the free fluid phase in equilibrium with the gel is
hypotonic and lower when the free fluid phase is hypertonic
[66]. In the renal medulla, which contains abundant interstitium
[67, 68] artd glycosaminoglycans [69—721, gel tension may be
especially important. The renin-angiotensin system contributes
to the control of medullary hemodynamics and the maintenance
of the medullary tonicity in sodium retaining states [73], Thus,
the interstitial gel tension may change in the same direction as
the interstitial hydrostatic pressure during sodium depletion,
and the reduction in the mechanical pressures acting on the
tubular wall may be underestimated by measurements of inter-
stitial hydrostatic pressure alone.
In summary, the experiments reported here indicate that the
development of DPT-RCD can be markedly influenced by a
variety of experimental conditions which have an effect on the
renin-angiotensin system and sodium metabolism. Whether
there is a cause-effect relationship between the changes in the
renal-angiotensin system and the development of the renal
cystic disease is uncertain. It seems likely, however, that the
renin-angiotensin system can influence the development of
renal cystic disease by the effects of angiotensin II on cell
growth and interstitial pressures and compliance. Our results
are consistent with the old observation [74] that "tubular
obstruction and anemic degeneration of the parenchyma from
circulatory disturbances in the same segment of the kidney"
facilitate the development of renal cysts.
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